Esperion settlement prevents generic NEXLETOL and NEXLIZET filing until 2040
Esperion (ESPR) reached a settlement agreement with a sixth ANDA filer that the filer will not market a generic version of NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid & ezetimibe) prior to April 19, 2040.
Story updates
12:01:31 PM UTC
SquawkNews
ANN ARBOR, Mich., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Esperion, a company wholly-owned by ARCHIMED, today announced that it has entered into a settlement agreement with Renata Limited (along with an affiliate). This agreement resolves the patent litigation brought by Esperion against Renata in respon…
12:01:49 PM UTC
SquawkNews
Esperion reached a settlement with Renata Limited, under which Renata will not market U.S. generics of NEXLETOL or NEXLIZET before Apr 19, 2040, subject to customary exceptions. Litigation with Aurobindo, MSN, and Sandoz continues.Material DetailsContext by AI AnalystThis is a mid-cycle legal win e…